Australia markets closed
  • ALL ORDS

    7,649.30
    -32.00 (-0.42%)
     
  • ASX 200

    7,342.60
    -27.60 (-0.37%)
     
  • AUD/USD

    0.7255
    -0.0044 (-0.60%)
     
  • OIL

    73.97
    +0.67 (+0.91%)
     
  • GOLD

    1,747.80
    -2.00 (-0.11%)
     
  • BTC-AUD

    58,120.53
    -3,690.35 (-5.97%)
     
  • CMC Crypto 200

    1,048.33
    -54.73 (-4.96%)
     
  • AUD/EUR

    0.6191
    -0.0020 (-0.32%)
     
  • AUD/NZD

    1.0346
    +0.0033 (+0.32%)
     
  • NZX 50

    13,259.55
    -46.37 (-0.35%)
     
  • NASDAQ

    15,281.99
    -34.59 (-0.23%)
     
  • FTSE

    7,051.48
    -26.87 (-0.38%)
     
  • Dow Jones

    34,759.84
    -4.98 (-0.01%)
     
  • DAX

    15,531.75
    -112.22 (-0.72%)
     
  • Hang Seng

    24,192.16
    -318.82 (-1.30%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     

Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the second quarter 2021 financial results and provide a business update.

Conference Call Information:

Date:

Wednesday, August 11

Time:

8:30 am Eastern Time

Domestic Dial-in:

(844) 615-6509

International Dial-in:

(918) 922-3148

Conference ID:

9484516

Webcast:

https://edge.media-server.com/mmc/p/ne5cqqtf

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting